Skip to main content

Advertisement

Log in

Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The vitelliform stage is the typical phenotypic manifestation of Best vitelliform macular dystrophy (BVMD). As yet, no study has focused specifically on the clinical changes occurring in the vitelliform stage over the follow-up.

Methods

The survey takes the form of a prospective observational study with a 5-year follow-up. Twenty-one eyes of 11 patients in the vitelliform stage were examined annually. The primary outcome was the identification of the changes in the vitelliform lesion over a 5-year follow-up. Secondary outcomes included changes in structural optical coherence tomography (OCT) parameters and the correlation with the BCVA variation over the follow-up.

Results

Spectral domain OCT at baseline showed one subform characterized by solid vitelliform deposition, in 81% of eyes, and another subform characterized by a combination of solid deposition and subretinal fluid, in 19% of eyes. Overall, 62% of eyes showed an increase in the area of vitelliform deposition. Once the maximal area was reached, a progressive flattening of the vitelliform deposition took place, with subsequent flattening of the vitelliform lesion and formation of subretinal fluid. Hyperreflective foci (HF) increased in number as long as the vitelliform area continued to expand, with no variation in HF when the vitelliform lesion flattened or the subretinal fluid formed.

Conclusions

The vitelliform stage reveals more subforms with clinical variations over the follow-up. Our data suggest that the substage before the flattening of the lesion, thus before the so-called subretinal fluid accumulates and when the visual acuity is still high, might offer the best opportunity for an optimal therapeutic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Gass JDM (1997) Best’s disease. In: Gass J (ed) Stereoscopic atlas of macular diseases. Diagnosis and treatment. Vol 1, 4th edn. Mosby, St Louis, pp 304–311

    Google Scholar 

  2. Boon CJF, Klevering B, Leroy BP et al (2009) The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Progr Ret Eye Res 28:187–205

    Article  CAS  Google Scholar 

  3. Booij JC, Boon CJF, van Schooneveld MJ et al (2010) Course of visual decline in relation to the Best1 genotype in vitelliform macular dystrophy. Ophthalmology 117:1415–1422

    Article  Google Scholar 

  4. Battaglia Parodi M, Castellino N, Iacono P et al (2018) Microperimetry in Best vitelliform macular dystrophy. Retina 38:841–848

    Article  Google Scholar 

  5. Battaglia Parodi M, Iacono P, Romano F, Bandello F (2018) Spectral domain optical coherence tomography features in different stages of Best vitelliform macular dystrophy. Retina 38:1041–1046

    Article  Google Scholar 

  6. Battaglia Parodi MB, Iacono P, Campa C et al (2014) Fundus autofluorescence patterns in Best vitelliform macular dystrophy. Am J Ophthalmol 158:1086–1092

    Article  Google Scholar 

  7. Battaglia Parodi M, Iacono P, Del Turco C et al (2015) Functional assessment of the fundus autofluorescence pattern in Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol 254:1297–1302

    Article  Google Scholar 

  8. Battaglia Parodi M, Romano F, Sacconi R et al (2018) Intraretinal hyperreflective foci in Best vitelliform macular dystrophy. Retina 38:2379–2386

    Google Scholar 

  9. Murdoch IE, Morris SS, Cousens SN (1998) People and eyes: statistical approaches in ophthalmology. Br J Ophthalmol 82:971–973

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alessandro Arrigo.

Ethics declarations

Conflict of interest

Francesco Bandello consultant for Allergan Inc. (Irvine, California, USA), Bayer Shering-Pharma (Berlin, Germany), Hoffmann-La-Roche (Basel, Switzerland), NTC Pharma, Novartis (Basel, Switzerland), SIFI, SOOFT, Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, USA). All other authors have no disclosures to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Battaglia Parodi, M., Romano, F., Arrigo, A. et al. Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study. Graefes Arch Clin Exp Ophthalmol 258, 297–301 (2020). https://doi.org/10.1007/s00417-019-04454-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-019-04454-4

Keywords

Navigation